First patents granted to Pharma in silica

Québec, January 29, 2024 – As of today, India is the first intellectual property authority to grant a patent for all three families of inventions relative to the OpKemo technology (optimized chemotherapy).

Applications inventions continue to progress in other territories, including North America and Europe, under the guidance of Northon Rose Fullbright intellectual property agents.

Update, September 2024: nine patents have been granted to Pharma in silica in China, India, Japan and Israel.

About Pharma in silica inc.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.

For more information

François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com

> all news